Insulin’s Contribution to Growth in Children and the Potential for Exercise to Mediate Insulin’s Action

1997 ◽  
Vol 9 (1) ◽  
pp. 18-32 ◽  
Author(s):  
Craig A. Horswill ◽  
William B. Zipf ◽  
C. Lawrence Kien ◽  
E. Bowie Kahle

Insulin is an anabolic hormone with stimulatory effects on glucose and amino acid uptake, possibly protein synthesis, and bone growth, and inhibitory effects on protein breakdown. The precise role of insulin in the growth of healthy children is unclear, but two clinical models can be examined to illustrate insulin’s potential role in the growth of children. The cystic fibrosis (CF) patient, who exhibits poor linear growth and low lean body mass, may exhibit inadequate insulin secretion or impaired insulin action. The obese child typically has an excess of peripheral insulin, an associated acceleration of linear growth, and an accretion of lean body mass and adipose tissue. Speculation is offered on the putative role of exercise in affecting insulin action and secretion, which in turn could impact growth in children with CF or obesity.

2014 ◽  
Vol 33 (1) ◽  
pp. 257-268 ◽  
Author(s):  
C. Narjoz ◽  
A. Cessot ◽  
A. Thomas-Schoemann ◽  
J. L. Golmard ◽  
O. Huillard ◽  
...  

Glia ◽  
2008 ◽  
Vol 56 (9) ◽  
pp. 990-997 ◽  
Author(s):  
Holten Aleksander Talgøy ◽  
Danbolt Niels Christian ◽  
Shimamoto Keiko ◽  
Gundersen Vidar

1986 ◽  
Vol 118 (1) ◽  
pp. 19-27 ◽  
Author(s):  
Denis Allemand ◽  
Guy De Renzis ◽  
Patrick Payan ◽  
Jean-Pierre Girard

2000 ◽  
Vol 11 (7) ◽  
pp. 1303-1309 ◽  
Author(s):  
PETER STENVINKEL ◽  
BENGT LINDHOLM ◽  
FREDRIK LÖNNQVIST ◽  
KRASSIMIR KATZARSKI ◽  
OLOF HEIMBÜRGER

Abstract. Leptin, secreted from fat cells, functions as a lipostat mechanism through modulation of satiety signals. Markedly elevated leptin levels have been documented in uremic patients, especially in those who are treated by peritoneal dialysis (PD). However, the role of hyperleptinemia in uremic patients is not clear, and it is not known whether elevated leptin levels contribute to uremic anorexia and changes in body composition. In this prospective study, serum leptin, C-reactive protein (CRP), plasma insulin, and body composition (dual-energy x-ray absorptiometry) were measured in 36 patients (53 ± 1 yr) close to start and after about 1 yr of PD. In addition, markers of dialysis adequacy and urea kinetics were followed during treatment with PD. During PD, the total body fat mass (20.5 ± 1.0 to 22.9 ± 1.3 kg ;P< 0.01), truncal fat mass (11.5 ± 0.7 to 13.2 ± 0.9 kg ;P< 0.001), and serum leptin levels (20.1 ± 3.8 to 35.6 ± 6.8 ng/ml ;P< 0.01) increased markedly, especially in patients with diabetes mellitus. Twenty-five PD patients that lost lean body mass during PD had significantly (P< 0.05) elevated initial CRP levels (14 ± 2 mg/L) compared to 11 patients (<10 mg/L) who gained lean body mass during PD. A significant increase in serum leptin levels (20.9 ± 4.2 to 42.7 ± 4.0 ng/ml ;P< 0.001) was observed in those patients who lost lean body mass, whereas no such change (18.4 ± 8.4 to 19.2 ± 6.4 ng/ml) was observed in the patients that gained lean body mass during PD treatment. The present longitudinal results demonstrate that serum leptin level and body fat content increase markedly during PD, especially in diabetic patients. Patients that lost lean body mass during PD had higher initial CRP levels and increased their serum leptin levels significantly during PD compared to those patients that gained lean body mass. Additional studies are therefore needed to elucidate the role of hyperleptinemia and inflammation in causing anorexia, protein-malnutrition, and changes in body composition during treatment with PD.


2017 ◽  
Vol 88 (S1) ◽  
pp. 78-82
Author(s):  
Špela Borštnar ◽  
Jelka Lindič ◽  
Andrej Škoberne ◽  
Luka Ležaič ◽  
Aljaž Sočan ◽  
...  

1972 ◽  
Vol 142 (2) ◽  
pp. 219-235 ◽  
Author(s):  
PAUL K. CHIEN ◽  
GROVER C. STEPHENS ◽  
PATRICK L. HEALEY

Sign in / Sign up

Export Citation Format

Share Document